Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
Affidea, the largest European provider of advanced diagnostics, outpatient and cancer care services announces a strategic partnership with Incepto, supplier and creator of artificial intelligence solutions in the medical, sector.
|LATTICE MEDICAL DEMARRE SES ESSAIS CLINIQUES 🚀|
Et voilà nous y sommes ! Après 3 ans de travail, nous annonçons le démarrage de nos essais cliniques et l’inclusion d’une première patiente éligible à la reconstruction mammaire avec #MATTISSE dans le cadre de son cancer du sein.
French medtech companies are tackling diabetes and innovating, as proven by the sheer number of patents filed in 2021. Each year, the National Industrial Property Institute (INPI)ranks the top patent filers, highlighting companies that invest in innovation.
Archamps, June 29th
, 2022 – Cathay Capital announced its investment in TransCure bioServices, alongside the management team and Financière Arbevel. With this transaction, TransCure bioServices will benefit from Cathay Capital’s healthcare expertise as well as its strategic, and financial support to accelerate its growth and global expansion
Paris, France, June 29, 2022 – 6:00 p.m. CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company specialized in the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, announces that the European Patent Office (EPO) has granted a new patent that strengthens Acticor Biotech’s patent portfolio. It provides protection for the use of glenzocimab in thrombotic diseases in Europe until 2036.
Paris, le 28 juin 2022 – Les startups Kap Code et ArcaScience, membres de la première promotion Future4care, annoncent leur partenariat. Il débouchera sur la mise à disposition de nouveaux outils de pharmacovigilance basés sur l’intelligence artificielle.
Telemedicine at the service of patients 🚀
We’re proud to announce a partnership with TeleClinic, Germany’s market leader for online consultations.
Launch of Vik Atopic Dermatitis in the United States
🇺🇸 After expanding to six countries this year, Vik Atopic Dermatitis completes the world tour with one more launch: the USA!
PKvitality announces the results of its 3rd clinical trial on humans
PKvitality’s mission is to enable everyone to contribute actively to their well-being and health through products that are simple and comfortable to use. Thus, its K’Watch Glucose smartwatch will be the world’s first CGM device that will track glucose levels discreetly and continuously at the wrist.
Latest Insights
Bordeaux, France December 15, 2021 – FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, an Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced further funding of €6 million bringing the Series B total to €21 million, giving FineHeart a cash runway until the end of 2023. This financing comes in addition to the €15 million raised in June 2021 with the pool of industrial and independent investors: Lauak Group, Doliam, FineHeart Founders’ Holding which brought together international private investors, mainly from the cardiology sector and the European investment fund Verve Ventures. They joined historical shareholders Irdi, Aquiti, Galia, Broadview Ventures, and M Capital.
Paris, February 7th 2017 – Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, today announced that
Paris, October 13, 2021 – Acticor Biotech, a clinical stage biotechnology company working on treatment for the acute phase of thrombotic diseases, today announces that it started at the end of September 2021 the recruitment in ACTISAVE, its international phase 2/3 adaptive study on glenzocimab (ACT017), a novel humanized monoclonal antibody fragment for use in patients with acute ischemic stroke.
Paris, France, November 4, 2021 at 06:30 pm CET – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT),
a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, today announces that the U.S Food and Drug Administration (FDA) has provided clearance for the initiation of a clinical trial in US with glenzocimab, a novel humanized monoclonal antibody fragment, for use in patients with acute ischemic stroke.
Towards a new standard for device indication: Implantation for temporary or permanent use • Easy removal with a beating heart